Publications by authors named "W P Klovekorn"
Article Synopsis
- The updated S2k guideline focuses on the diagnosis and treatment of rosacea, a common chronic skin disease primarily affecting the face, with symptoms evolving from flushing to severe inflammatory lesions.
- Treatment recommendations include avoiding triggers and using topical treatments like metronidazole, azelaic acid, and ivermectin; vasoconstrictors for persistent redness; and systemic therapy for severe cases, primarily low-dose doxycycline.
- Additional care for ocular rosacea involves lid hygiene and treatments such as ciclosporin eye drops and azithromycin.
Background: Two phase III trials of photodynamic therapy (PDT) with BF-200 ALA, a recently approved nanoemulsion formulation of 5-aminolaevulinic acid (ALA) demonstrated high clearance rates in mild-to-moderate actinic keratosis (AK). The comparison to a registered methyl aminolaevulinate (MAL) cream demonstrated significantly superior total patient clearance rates.
Objectives: To evaluate long-term efficacy and safety of PDT for AK 6 and 12 months after the last PDT with BF-200 ALA, MAL or placebo.
Background: Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) or its methylester [methyl-5-aminolaevulinate (MAL) or 5-amino-4-oxopentanoate] was recently ranked as first-line therapy for the treatment of actinic keratosis (AK) and is an accepted therapeutic option for the treatment of neoplastic skin diseases. BF-200 ALA (Biofrontera Bioscience GmbH, Leverkusen, Germany) is a gel formulation of ALA with nanoemulsion for the treatment of AK which overcomes previous problems of ALA instability and improves skin penetration.
Objectives: To evaluate the efficacy and safety of PDT of AKs with BF-200 ALA in comparison with a registered MAL cream and with placebo.